T1D Fund portfolio company i2O Therapeutics is developing several products leveraging GLP-1s, initially for T2D, including a refillable, implantable GLP-1 device that delivers 6 months worth of the hormone, an oral form of long acting GLP-1, as well as a combined oral GLP-1 with Amylin (another important pancreatic hormone)
However, such results must be interpreted cautiously, as the small sample size and short study durations preclude comment on the long-term effects and safety of GLP-1 RAs in the treatment of psoriasis, ultimately limiting the ability to draw definitive, robust conclusions
A Receptor Subunit Selectivity of Alcohol Actions"
Key variants such as GLP1R rs6923761, GIPR rs1800437, and genes affecting NAD-dependent pathways (like SIRT1 and NAMPT) can reveal whether your genetic profile supports complementary NAD therapy alongside tirzepatide